Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
32.31
+0.64 (2.02%)
At close: Aug 13, 2025, 4:00 PM
32.30
-0.01 (-0.03%)
After-hours: Aug 13, 2025, 4:04 PM EDT
Galapagos NV Revenue
Galapagos NV had revenue of 65.29M EUR in the quarter ending June 30, 2025, a decrease of -16.16%. This brings the company's revenue in the last twelve months to 275.61M, up 5.43% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
275.61M EUR
Revenue Growth
+5.43%
P/S Ratio
6.60
Revenue / Employee
391,490 EUR
Employees
704
Market Cap
2.14B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GLPG News
- 6 days ago - Galapagos Creates New Subscription Right Plan - GlobeNewsWire
- 7 days ago - Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma - GlobeNewsWire
- 21 days ago - Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation - GlobeNewsWire
- 21 days ago - Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors - GlobeNewsWire
- 21 days ago - Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update - GlobeNewsWire
- 7 weeks ago - Galapagos Appoints Aaron Cox as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 - GlobeNewsWire
- 2 months ago - Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL - GlobeNewsWire